Clinical Trials List
2025-04-01 - 2032-12-31
Phase III
Recruiting5
ICD-10C54.1
Malignant neoplasm of endometrium
ICD-10C54.2
Malignant neoplasm of myometrium
ICD-10C54.3
Malignant neoplasm of fundus uteri
ICD-10C54.9
Malignant neoplasm of corpus uteri, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9182.0
Malignant neoplasm of corpus uteri, except isthmus
-
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/05/13
Investigators and Locations
Co-Principal Investigator
- Cheng-Yang Chou Division of Obstetrics & Gynecology
- 林語涵 無
- 黃蘭茵 無
- Meng-Ru Shen Division of Obstetrics & Gynecology
- Keng-Fu Hsu 無
- 吳珮瑩 Division of Obstetrics & Gynecology
- 梁玉玲 無
- 鄭雅敏 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Cheng-Tao Lin Division of Obstetrics & Gynecology
- 張淑涵 無
- 黃意婷 無
- Angel Chao 無
- 容世明 無
- 陳威君 無
- 黃寬仁 無
- Gigin Lin 無
- 張宸邠 無
- 黃彥綾 無
- HSIU-JUNG TUNG 無
- 周宏學 無
- Ting-Chang Chang 無
- Yun-Hsin Tang 無
- Huei-Jean Huang 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 吳佳穎
- 郭千慈
- 施怡倫
- 陳宇立
- YING-CHENG CHIANG Division of Obstetrics & Gynecology
- BOR-CHING SHEU
- - -
- 張文君
- 戴依柔
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
42 participants
-
Global
1123 participants
